Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

64. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults

Liraglutide (Saxenda) for weight loss in non-diabetic obese adults Liraglutide (Saxenda) for weight loss in non-diabetic obese adults Liraglutide (Saxenda) for weight loss in non-diabetic obese adults HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Liraglutide (Saxenda) for weight loss in non-diabetic obese adults. Lansdale: HAYES, Inc (...) .. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Adult; Anti-Obesity Agents; Humans; Liraglutide; Obesity; Weight Loss Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo

Health Technology Assessment (HTA) Database.2015

65. Liraglutide and the Preservation of Pancreatic beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial

Liraglutide and the Preservation of Pancreatic beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial 25249651 2014 11 21 2015 06 16 2015 11 19 1935-5548 37 12 2014 Dec Diabetes care Diabetes Care Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. 3270-8 10.2337/dc14-0893 Clinical studies evaluating the effects of medications on β-cell function in type 2 diabetes (T2DM) are compromised by an inability to determine the actual baseline (...) degree of β-cell dysfunction independent of the reversible dysfunction induced by hyperglycemia (glucotoxicity). Short-term intensive insulin therapy (IIT) is a strategy for eliminating glucotoxicity before randomization. This study determined whether liraglutide can preserve β-cell function over 48 weeks in early T2DM following initial elimination of glucotoxicity with IIT. In this double-blind, randomized, placebo-controlled trial, 51 patients with T2DM of 2.6 ± 1.9 years' duration and an A1C

EvidenceUpdates2014

66. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. BACKGROUND: Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial, we compared the safety and efficacy of once-weekly dulaglutide with that of once-daily liraglutide in metformin-treated (...) ) or once-daily liraglutide (1·8 mg). Randomisation was done according to a computer-generated random sequence with an interactive voice response system. Participants and investigators were not masked to treatment allocation. The primary outcome was non-inferiority (margin 0·4%) of dulaglutide compared with liraglutide for change in HbA1c (least-squares mean change from baseline) at 26 weeks. Safety data were collected for a further 4 weeks' follow-up. Analysis was by intention to treat. This study

Lancet2014

67. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs 24199745 2014 02 05 2014 11 17 2015 11 19 1463-1326 16 3 2014 Mar Diabetes, obesity & metabolism Diabetes Obes Metab A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. 273-5 10.1111/dom.12230 We evaluated the relationship between liraglutide and acute (...) pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme. Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US commercial health insurance claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months. We estimated incidence rates (IR/100 000 person-years), rate ratio (RR) and 95% confidence intervals (CI) of new insurance

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

68. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo A network meta-analysis to compare glycaemic control in patients (...) with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo Scott DA, Boye KS, Timlin L, Clark JF, Best JH CRD summary This network meta-analysis concluded that exenatide once weekly and liraglutide (1.2mg or 1.8mg) had similar effects in improving the control of blood glucose in people with type 2 diabetes. The quality of the included trials and the applicability of the results to UK practice are uncertain, meaning

DARE.2014

70. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. 25018121 2014 10 13 2015 01 01 2015 11 19 1474-547X 384 9951 2014 Oct 11 Lancet (London, England) Lancet Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. 1349-57 10.1016/S0140-6736(14)60976-4 S0140 (...) -6736(14)60976-4 Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial, we compared the safety and efficacy of once-weekly dulaglutide with that of once-daily liraglutide in metformin-treated patients with uncontrolled type 2 diabetes. We did a phase 3, randomised, open-label, parallel-group study at 62 sites in nine countries between June 20, 2012, and Nov 25, 2013

Lancet2014

71. Liraglutide for obesity or overweight in patients with associated co-morbidities

Liraglutide for obesity or overweight in patients with associated co-morbidities Liraglutide for obesity or overweight in patients with associated co-morbidities Liraglutide for obesity or overweight in patients with associated co-morbidities NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Liraglutide for obesity

Health Technology Assessment (HTA) Database.2013

72. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. 23141817 2013 01 14 2013 02 01 2015 11 19 1474-547X 381 9861 2013 Jan 12 Lancet (London, England) Lancet Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. 117-24 10.1016/S0140-6736(12)61267-7 S0140-6736(12)61267-7 Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have (...) been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes. We compared the efficacy and safety of exenatide once weekly with liraglutide once daily in patients with type 2 diabetes. We did a 26 week, open-label, randomised, parallel-group study at 105 sites in 19 countries between Jan 11, 2010, and Jan 17, 2011. Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1

Lancet2013

73. Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets 22584132 2012 06 22 2012 10 23 2016 12 15 1935-5548 35 7 2012 Jul Diabetes care Diabetes Care Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. 1446-54 10.2337/dc11-1928 We evaluated the addition of liraglutide to metformin (...) in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks' open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

74. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer Alves C, Batel-Marques F, Macedo AF CRD summary The review found that the available published evidence was insufficient to support an increased risk of acute (...) pancreatitis or cancer associated with GLP-1 agonist use in patients with type 2 diabetes. These conclusions appear to be a reliable reflection of the available published data. Authors' objectives To evaluate the risk of developing acute pancreatitis or cancer in patients with type 2 diabetes taking a GLP-1 agonist (exenatide or liraglutide). Searching MEDLINE, EMBASE, The Cochrane Library and ClinicalTrials.gov were searched to May 2012 for studies published in English; search strategies were reported

DARE.2012

75. Liraglutide (Victoza) in type 2 diabetes. Similar to exenatide

Liraglutide (Victoza) in type 2 diabetes. Similar to exenatide 2011. DAR No 11. Liraglutide (Victoza®) in type 2 diabetes - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 11. Liraglutide (Victoza®) in type 2 diabetes DAR No 11. Liraglutide (Victoza®) in type 2 diabetes Content tools Share it Similar to exenatide The efficacy of liraglutide is similar to glimepiride and slightly higher than glargine and exenatide, although

Drug and Therapeutics Bulletin of Navarre (Spain)2011

77. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents Valentine (...) WJ, Palmer AJ, Lammert M, Langer J, Brandle M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of once-daily liraglutide versus exenatide twice daily in patients with type 2 diabetes who had

NHS Economic Evaluation Database.2011

78. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Lee WC, Conner C, Hammer M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of liraglutide (1.2 or 1.8mg) compared with rosiglitazone (4mg), both combined with glimepiride, for the management of adults with type 2 diabetes mellitus. The authors concluded that liraglutide (particularly 1.2mg

NHS Economic Evaluation Database.2011

79. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

Liraglutide for the treatment of type 2 diabetes mellitus (TA203) Liraglutide for the treatment of type 2 diabetes mellitus | Guidance and guidelines | NICE Liraglutide for the treatment of type 2 diabetes mellitus Technology appraisal guidance [TA203] Published date: 27 October 2010 Last updated: 01 December 2014 Guidance . Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.

National Institute for Health and Clinical Excellence - Technology Appraisals2010